Nivolumab: tested in a combination
680 studies: another drug in the study is under test too. Page 1 of 7. Open to participants first (135), then studies with results posted, then the rest; newest registration first within each.
- NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCCNot yet recruitingNCT07919717Phase 2Report a problem
- MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingNCT07885709Phase 2Report a problem
- A Study of Treatment Delivery Preference In People With Kidney CancerRecruitingNCT07872553Phase 4Report a problem
- Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingNCT07741565Early Phase 1Report a problem
- NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) MelanomaRecruitingNCT07740941Phase 2Report a problem
- Timing of Immunotherapy in MelanomaRecruitingNCT07696715Not applicableReport a problem
- Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular CarcinomaRecruitingNCT07689175Phase 2Report a problem
- Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma PatientsNot yet recruitingNCT07679841Phase 1/2Report a problem
- Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPGNot yet recruitingNCT07644312Phase 2Report a problem
- A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung CancerRecruitingNCT07603856Phase 2Report a problem
- MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.RecruitingNCT07574047Phase 2Report a problem
- Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin LymphomaNot yet recruitingNCT07572123Phase 2/3Report a problem
- Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR CancersEnrolling by invitationNCT07542262Phase 2Report a problem
- ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and RelatlimabRecruitingNCT07504796Phase 2Report a problem
- Neoadjuvant Immunotherapy for Patients With High-risk Eye MelanomaRecruitingNCT07501117Phase 1Report a problem
- A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular CarcinomaRecruitingNCT07482059Phase 1/2Report a problem
- A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In IndiaNot yet recruitingNCT07459543Phase 4Report a problem
- A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue SarcomasRecruitingNCT07444619Phase 1Report a problem
- Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in SloveniaRecruitingNCT07422779Not applicableReport a problem
- Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung DiseaseNot yet recruitingNCT07420439Phase 2Report a problem
- Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal CancerNot yet recruitingNCT07403877Phase 2Report a problem
- First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung CancerRecruitingNCT07355205Phase 1/2Report a problem
- The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.Not yet recruitingNCT07338981Phase 3Report a problem
- Hepzato Kit and Opdualag for Metastatic Melanoma and Liver MetastasisRecruitingNCT07281924Phase 1/2Report a problem
- Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHLRecruitingNCT07234487Phase 2Report a problem
- Neo-adjuvant Immunotherapy in Patients With Localized MelanomaRecruitingNCT07230613Phase 2Report a problem
- Impact of Circadian Rhythm on ImmunotherapyRecruitingNCT07224971Phase 2Report a problem
- Patient Preference for Subcutaneous vs. Intravenous Immune TherapyRecruitingNCT07223424Phase 2Report a problem
- Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized TrialNot yet recruitingNCT07190027Phase 1/2Report a problem
- Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care ImmunotherapiesRecruitingNCT07174453Phase 3Report a problem
- Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME TrialRecruitingNCT07155317Phase 2Report a problem
- Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint BlockadeRecruitingNCT07130032Phase 2Report a problem
- NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyRecruitingNCT07121374Phase 1/2Report a problem
- Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular CancerRecruitingNCT07075120Phase 1Report a problem
- Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCLRecruitingNCT07013565Phase 2Report a problem
- Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)RecruitingNCT06999980Phase 2Report a problem
- Nivo40-AVD for Advanced Classic Hodgkin LymphomaRecruitingNCT06984146Phase 2Report a problem
- Saci Nivo Rela for TNBCRecruitingNCT06963905Phase 1/2Report a problem
- Cabozantinib and Nivolumab Among Older Patients With Renal Cell CarcinomaRecruitingNCT06934057Phase 4Report a problem
- Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)RecruitingNCT06926790Phase 2Report a problem
- A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal MetastasesRecruitingNCT06901817Phase 2Report a problem
- Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade GliomaEnrolling by invitationNCT06896110Phase 1Report a problem
- Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric CancerNot yet recruitingNCT06888037Phase 2Report a problem
- Towards Cure Via Only Ultra-short ICB in CSCCRecruitingNCT06823479Phase 2Report a problem
- PD-1 Inhibitors Maintenance for cHL Post-autoHCTRecruitingNCT06812858Phase 2Report a problem
- A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung CancerRecruitingNCT06800339Phase 1Report a problem
- SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III MelanomaRecruitingNCT06794775Phase 3Report a problem
- Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin LymphomaRecruitingNCT06745076Phase 2Report a problem
- Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain MetastasesRecruitingNCT06712927Phase 2Report a problem
- MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric GliomasRecruitingNCT06712875Phase 1/2Report a problem
- Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)RecruitingNCT06683755Phase 1/2Report a problem
- Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk RecurrenceRecruitingNCT06682728Phase 2Report a problem
- Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With ChemotherapyRecruitingNCT06667154Phase 2Report a problem
- Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell CarcinomaRecruitingNCT06624475Phase 2Report a problem
- A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%RecruitingNCT06561386Phase 3Report a problem
- The Sagittarius TrialRecruitingNCT06490536Phase 3Report a problem
- Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant MelanomaRecruitingNCT06488482Phase 3Report a problem
- A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced CancersRecruitingNCT06422403Phase 2Report a problem
- DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLCRecruitingNCT06364917Phase 2Report a problem
- CARE1 Pragmatic Clinical TrialRecruitingNCT06364631Phase 3Report a problem
- Investigator Grant (IG) 2022 27746RecruitingNCT06341478Not applicableReport a problem
- Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced MelanomaRecruitingNCT06295159Phase 2Report a problem
- Intradermal Ipilimumab and Nivolumab in High Risk Stage II MelanomaRecruitingNCT06240143Phase 1/2Report a problem
- Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent CancerRecruitingNCT06208657Phase 1/2Report a problem
- Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCCRecruitingNCT06170710Phase 2Report a problem
- Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain MetastasesRecruitingNCT06163820Phase 1/2Report a problem
- A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ CancerRecruitingNCT06158919Not applicableReport a problem
- Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ CancerRecruitingNCT06121700Phase 2Report a problem
- A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)RecruitingNCT06064097Phase 2Report a problem
- Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal CancerNot yet recruitingNCT06047015Phase 1/2Report a problem
- Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction ImmunochemotherapyNot yet recruitingNCT06031597Phase 3Report a problem
- Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruitingNCT06031233Phase 4Report a problem
- Nivolumab in Children and Adults With Nasopharyngeal CarcinomaRecruitingNCT06019130Phase 2Report a problem
- Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain MetastasesRecruitingNCT05909618Phase 2Report a problem
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerRecruitingNCT05896839Phase 1/2Report a problem
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingNCT05845450Phase 2Report a problem
- Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck CancersNot yet recruitingNCT05835804Phase 2Report a problem
- Cryoablation+Ipilimumab+Nivolumab in MelanomaRecruitingNCT05779423Phase 2Report a problem
- First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)RecruitingNCT05749900Phase 1/2Report a problem
- Intraperitoneal Immune Checkpoint Inhibitor for Malignant AscitesEnrolling by invitationNCT05745233Not applicableReport a problem
- Immunotherapy in Patients With Early dMMR Rectal CancerRecruitingNCT05732389Phase 2Report a problem
- Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland CarcinomaRecruitingNCT05727410Phase 2Report a problem
- Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical StudyRecruitingNCT05721651Phase 2Report a problem
- Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain MetastasesRecruitingNCT05704647Phase 2Report a problem
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingNCT05675410Phase 3Report a problem
- Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid MesotheliomaRecruitingNCT05647265Phase 2Report a problem
- Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid SyndromeNot yet recruitingNCT05597800Phase 2Report a problem
- Treatment Strategy for Relapsed/Refractory Hodgkin LymphomaRecruitingNCT05595447Phase 2/3Report a problem
- Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver MetastasesNot yet recruitingNCT05588297Phase 2Report a problem
- Nivolumab-ipilimumab and Chemoradiation for Cervical CancerRecruitingNCT05492123Phase 2Report a problem
- Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC StudyRecruitingNCT05361720Phase 2Report a problem
- 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCCRecruitingNCT05317000Phase 2Report a problem
- Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRCRecruitingNCT05310643Phase 2Report a problem
- Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of PersistenceRecruitingNCT05310591Phase 1/2Report a problem
- Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell LymphomaRecruitingNCT05272384Phase 1Report a problem
- Chemoradiotherapy With Targeted Immunotherapy in Pediatric LymphomaRecruitingNCT05253495Phase 2Report a problem
- Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder CancerRecruitingNCT05203913Phase 2Report a problem
- BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyRecruitingNCT05136196Phase 2Report a problem
- Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic CancerRecruitingNCT05088889Phase 1Report a problem
- A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal MelanomaRecruitingNCT05077280Phase 2Report a problem